Company: ISRG
Filing Date: 2025-07-23
Form Type: 10-Q
Source: 0001035267-25-000192
Chunk: 75

Company: INTUITIVE SURGICAL INC
Filing Date: 2025-07-23
Form: 10-Q
Item: Item 1
Chunk 75
---
 partially offset by lower legal expenses and lower litigation charges.

Selling, general, and administrative expenses for the six months ended June 30, 2025, increased by 11% to $1.12 billion, compared to $1.02 billion for the six months ended June 30, 2024. The increase in selling, general, and administrative expenses for the six months ended June 30, 2025, was primarily driven by higher headcount and personnel-related expenses, including share-based compensation expense.

Selling, general, and administrative expenses for the three and six months ended June 30, 2025, included share-based compensation expense of $86.3 million and $168.6 million, respectively, compared with $79.6 million and $147.8 million for the three and six months ended June 30, 2024, respectively. Selling, general, and administrative expenses for the three and six months ended June 30, 2025, included intangible assets amortization expense of $0.1 million and $0.6 million, respectively, compared with $0.8 million and $1.6 million for the three and six months ended June 30, 2024, respectively.

Research and Development Expenses

Research and development costs are expensed as incurred and primarily include costs associated with the design, development, testing, and significant enhancement of our products. Our main product development initiatives include multi-port, Ion, and SP platform investments as well as digital products and services.

Research and development expenses for the three months ended June 30, 2025, increased by 12% to $313 million, compared to $280 million for the three months ended June 30, 2024. Research and development expenses for the six months ended June 30, 2025, increased by 11% to $630 million, compared to $565 million for the six months ended June 30, 2024. The increase in research and development expenses for the three and six months ended June 30, 2025, was primarily driven by higher headcount and personnel-related expenses, including share-based compensation expense, and other project costs incurred to support a broad set of product development initiatives.

Research and development expenses for the three and six months ended June 30, 2025, included share-based compensation expense of $74.7 million and $143.7 million, respectively, compared with $65.6 million and $123.3 million for the three and six months